Form 4: Intra-Cellular Therapies Executive Vice President Sanjeev Narula Reports Stock Option and Restricted Stock Unit Grants

Executive Vice President and CFO of Intra-Cellular Therapies, Sanjeev Narula, reports the acquisition of stock options and restricted stock units.

Summary

• On August 12, 2024, Sanjeev Narula, Executive Vice President & CFO of Intra-Cellular Therapies, Inc., was granted stock options for 17,251 shares and 35,046 restricted stock units (RSUs).
• The stock options have an exercise price of $74.90 and expire on August 11, 2034.
• The options vest in three equal installments on August 12, 2025, August 12, 2026, and August 12, 2027.
• The RSUs also vest in three equal installments on August 12, 2025, August 12, 2026, and August 12, 2027.
• Each RSU represents the right to receive one share of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, aligning management interests with shareholders through equity-based incentives.

Positives

• The grant of stock options and RSUs aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders (officers, directors, or those holding more than 10% of the company's shares) buy or sell the company's securities. This filing indicates compensation in the form of stock options and restricted stock units to a key executive.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align executive interests with shareholder value.
• Comparable companies such as Biogen, Amgen, and Vertex Pharmaceuticals also utilize stock options and RSUs as part of their executive compensation packages.
• The vesting schedules (one-third annually over three years) are typical for these types of grants.

Stakeholder Impact

• Shareholders may view the grant of stock options and RSUs positively, as it incentivizes management to improve company performance and increase shareholder value.
• Employees may see this as a positive sign, indicating the company's commitment to rewarding its executives.

Key Dates